Amplia Therapeutics Limited (INNMF)
Amplia Therapeutics Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Melbourne, VIC, AU. The stock last traded at $0.10, up 0.00% on the session, giving a market capitalisation of $51.3M. On trailing twelve-month figures it carries a trailing P/E of -8.38, a net margin of 0.0%. Its beta of -0.40 implies it has historically moved less than the broad market.
Established in 2000 and headquartered in Melbourne, Australia, Amplia Therapeutics Limited is a pharmaceutical firm dedicated to the discovery and development of focal adhesion kinase (FAK) inhibitors. The company's therapeutic endeavors are concentrated on oncology (cancer) and chronic fibrotic diseases. Its drug development pipeline includes AMP945, a FAK inhibitor that has successfully completed Phase I clinical trials and is being explored for its efficacy in treating pancreatic cancer, idiopathic pulmonary fibrosis, and a broader spectrum of cancerous and fibrotic conditions. Another compound, AMP886, is also under development for potential applications in cancer and fibrotic disorders. Amplia Therapeutics maintains a strategic collaboration with the Garvan Institute of Medical Research in Sydney, and the company adopted its current name in September 2018, having previously operated as Innate Immunotherapeutics Limited.
Amplia Therapeutics Limited is most often compared with the following Healthcare names: